Amgen Statement On Aranesp Manuscript In The Journal Of Clinical Oncology
"The '103 Anemia of Cancer' study, a Phase 3 trial designed to test whether anemic patients with active cancer not receiving concurrent chemotherapy or radiotherapy benefit from treatment with Aranesp, was previously reported by Amgen when results became available in 2007. The results of this study were provided to regulatory agencies, communicated to physicians through a 'Dear Healthcare Provider' letter, and presented at a scientific conference and other venues throughout last year.
"Amgen is committed to ensuring physicians and their patients have the most up-to-date information on its medicines, including both positive and negative results from clinical trials."
http://www.amgen.com/
Amgen declaraþie pe manuscris cu Aranesp în Jurnalul Oficial al clinice de oncologie - Amgen Statement On Aranesp Manuscript In The Journal Of Clinical Oncology - articole medicale engleza - startsanatate